Veru (NASDAQ:VERU) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Veru (NASDAQ:VERU) released its quarterly earnings data on Wednesday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.15, Zacks reports. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $1.90 million.

Here are the key takeaways from Veru’s conference call:

• Veru highlighted positive Phase 2b QUALITY data for enobosarm plus semaglutide, saying it preserved lean mass and reduced the proportion of patients with a clinically significant decline in stair climb power versus semaglutide alone.
• The company said the 3 mg enobosarm arm produced a statistically significant 59.8% relative reduction in patients with at least a 10% decline in stair climb power, while the 6 mg arm showed a 44.1% relative reduction.
• Veru is now running the Phase 2b plateau study in older adults with obesity to test whether enobosarm can help patients break through the common GLP-1 weight-loss plateau and generate incremental weight loss while preserving function and bone health.
• Management said the first interim analysis for the plateau study is expected in Q1 calendar 2027, and that enrollment is progressing well and remains on track.
• Financially, Veru ended the quarter with $27.6 million in cash and restricted cash, and management said this should fund operations beyond the interim analysis. The quarterly net loss from continuing operations also improved to $3.1 million from $7.9 million a year ago.

Veru Stock Performance

Veru stock opened at $2.17 on Friday. The firm has a market cap of $34.81 million, a price-to-earnings ratio of -1.67 and a beta of -1.19. The firm has a 50 day moving average price of $2.34 and a two-hundred day moving average price of $2.44. Veru has a 52-week low of $2.05 and a 52-week high of $7.40.

Institutional Investors Weigh In On Veru

Several large investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. grew its position in shares of Veru by 11.9% during the 2nd quarter. Osaic Holdings Inc. now owns 262,820 shares of the company’s stock worth $152,000 after buying an additional 27,954 shares during the period. Marshall Wace LLP bought a new position in shares of Veru during the 2nd quarter worth about $220,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Veru in the 3rd quarter valued at about $110,000. Raymond James Financial Inc. increased its position in Veru by 48.3% in the 2nd quarter. Raymond James Financial Inc. now owns 206,405 shares of the company’s stock valued at $120,000 after buying an additional 67,178 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Veru during the 3rd quarter worth approximately $38,000. Institutional investors and hedge funds own 47.16% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Wall Street Zen downgraded Veru from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.